Academic Support Boosts Agenus And Prophage G-200

10-02-2014 Seeking AlphaComments (0)

AgenusBiotechnologyOncologyUSA

Academic Support Boosts Agenus And Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme (GBM) as 'exciting' and a 'very promising therapy'. Further to this, in an independent editorial, John Sampson, professor of neurosurgeryat Duke University called the results 'impressive' and also said they represent a 'very promising therapy' in patients seeking GBM treatment. It is one thing when a hedge fund or other trading entity publishes positive reviews of a biotech company. It is another thing when that review comes from within the biotech trade itself.

The nature of this type of academic editorial is such that its content is often much more reliably indicative of success or failure than other types of published content from within the investment world. Theses' are inquisitive in nature and rely



Read more on Seeking Alpha

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top